3923 related articles for article (PubMed ID: 31294382)
61. Factors That Predict High Health Care Utilization and Costs for Patients With Inflammatory Bowel Diseases.
Limsrivilai J; Stidham RW; Govani SM; Waljee AK; Huang W; Higgins PD
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):385-392.e2. PubMed ID: 27645518
[TBL] [Abstract][Full Text] [Related]
62. Inequities in Rural and Urban Health Care Utilization Among Individuals Diagnosed With Inflammatory Bowel Disease: A Retrospective Population-Based Cohort Study From Saskatchewan, Canada.
Peña-Sánchez JN; Osei JA; Rohatinsky N; Lu X; Risling T; Boyd I; Wicks K; Wicks M; Quintin CL; Dickson A; Fowler SA
J Can Assoc Gastroenterol; 2023 Apr; 6(2):55-63. PubMed ID: 37025513
[TBL] [Abstract][Full Text] [Related]
63. Health Services Utilization, Specialist Care, and Time to Diagnosis with Inflammatory Bowel Disease in Immigrants to Ontario, Canada: A Population-Based Cohort Study.
Benchimol EI; Manuel DG; Mojaverian N; Mack DR; Nguyen GC; To T; Guttmann A
Inflamm Bowel Dis; 2016 Oct; 22(10):2482-90. PubMed ID: 27556836
[TBL] [Abstract][Full Text] [Related]
64. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
65. A comprehensive review and update on Crohn's disease.
Gajendran M; Loganathan P; Catinella AP; Hashash JG
Dis Mon; 2018 Feb; 64(2):20-57. PubMed ID: 28826742
[TBL] [Abstract][Full Text] [Related]
66. Health Care utilization in elderly onset inflammatory bowel disease: a population-based study.
Nguyen GC; Sheng L; Benchimol EI
Inflamm Bowel Dis; 2015 Apr; 21(4):777-82. PubMed ID: 25738376
[TBL] [Abstract][Full Text] [Related]
67. Rural and urban disparities in the care of Canadian patients with inflammatory bowel disease: a population-based study.
Benchimol EI; Kuenzig ME; Bernstein CN; Nguyen GC; Guttmann A; Jones JL; Potter BK; Targownik LE; Catley CA; Nugent ZJ; Tanyingoh D; Mojaverian N; Underwood FE; Siddiq S; Otley AR; Bitton A; Carroll MW; deBruyn JC; Dummer TJ; El-Matary W; Griffiths AM; Jacobson K; Leddin D; Lix LM; Mack DR; Murthy SK; Peña-Sánchez JN; Singh H; Kaplan GG;
Clin Epidemiol; 2018; 10():1613-1626. PubMed ID: 30519110
[TBL] [Abstract][Full Text] [Related]
68. The 2023 Impact of Inflammatory Bowel Disease in Canada: Executive Summary.
Windsor JW; Kuenzig ME; Murthy SK; Bitton A; Bernstein CN; Jones JL; Lee K; Targownik LE; Peña-Sánchez JN; Rohatinsky N; Ghandeharian S; Im JHB; Davis T; Weinstein J; Goddard Q; Benchimol EI; Kaplan GG
J Can Assoc Gastroenterol; 2023 Sep; 6(Suppl 2):S1-S8. PubMed ID: 37674500
[TBL] [Abstract][Full Text] [Related]
69. Changes to surgical and hospitalization rates of pediatric inflammatory bowel disease in Ontario, Canada (1994-2007).
Benchimol EI; Guttmann A; To T; Rabeneck L; Griffiths AM
Inflamm Bowel Dis; 2011 Oct; 17(10):2153-61. PubMed ID: 21910177
[TBL] [Abstract][Full Text] [Related]
70. Incidence and Treatment of Patients Diagnosed With Inflammatory Bowel Diseases at 60 Years or Older in Sweden.
Everhov ÅH; Halfvarson J; Myrelid P; Sachs MC; Nordenvall C; Söderling J; Ekbom A; Neovius M; Ludvigsson JF; Askling J; Olén O
Gastroenterology; 2018 Feb; 154(3):518-528.e15. PubMed ID: 29102619
[TBL] [Abstract][Full Text] [Related]
71. Appropriateness of immunosuppressive drugs in inflammatory bowel diseases assessed by RAND method: Italian Group for IBD (IG-IBD) position statement.
Caprilli R; Angelucci E; Cocco A; Viscido A; Annese V; Ardizzone S; Biancone L; Castiglione F; Cottone M; Meucci G; Paoluzi P; Papi C; Sturniolo GC; Vecchi M
Dig Liver Dis; 2005 Jun; 37(6):407-17. PubMed ID: 15893279
[TBL] [Abstract][Full Text] [Related]
72. Health Care Use by a Population-Based Cohort of Children With Inflammatory Bowel Disease.
Singh H; Nugent Z; Targownik LE; El-Matary W; Brownell M; Bernstein CN
Clin Gastroenterol Hepatol; 2015 Jul; 13(7):1302-1309.e3. PubMed ID: 25638585
[TBL] [Abstract][Full Text] [Related]
73. Assessing gastroenterologist and patient acceptance of biosimilars in ulcerative colitis and Crohn's disease across Germany.
Sullivan E; Piercy J; Waller J; Black CM; Kachroo S
PLoS One; 2017; 12(4):e0175826. PubMed ID: 28410403
[TBL] [Abstract][Full Text] [Related]
74. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
75. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
Magro F; Portela F
BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
[TBL] [Abstract][Full Text] [Related]
76. Integrated Care Models: Optimizing Adult Ambulatory Care in Inflammatory Bowel Disease.
Schoenfeld R; Nguyen GC; Bernstein CN
J Can Assoc Gastroenterol; 2020 Feb; 3(1):44-53. PubMed ID: 34169226
[TBL] [Abstract][Full Text] [Related]
77. [ECONOMIC BURDEN AND CURRENT STATUS OF THE DRUG SUPPLY MANAGEMENT FOR IMMUNE INFLAMMATORY DISEASES (BY EXAMPLE OF ULCERATIVE COLITIS AND CROHN'S DISEASE)].
Veselov AV; Belousova EA; Bakulin IG; Uspenskiy YP; Dreval RO; Shkurko TV; Kashnikov BN; Fominykh YA; Knyazev OV; Romanov RI; Skalinskaia MI; Shipitsyn VV
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2020 Oct; 28(Special Issue):1137-1145. PubMed ID: 33219771
[TBL] [Abstract][Full Text] [Related]
78. Economic Burden and Health Care Access for Patients With Inflammatory Bowel Diseases in China: Web-Based Survey Study.
Yu Q; Zhu C; Feng S; Xu L; Hu S; Chen H; Chen H; Yao S; Wang X; Chen Y
J Med Internet Res; 2021 Jan; 23(1):e20629. PubMed ID: 33399540
[TBL] [Abstract][Full Text] [Related]
79. Changes in Direct Healthcare Costs before and after the Diagnosis of Inflammatory Bowel Disease: A Nationwide Population-Based Study.
Lee J; Im JP; Han K; Kim J; Lee HJ; Chun J; Kim JS
Gut Liver; 2020 Jan; 14(1):89-99. PubMed ID: 31158951
[No Abstract] [Full Text] [Related]
80. Home Infliximab Infusions Are Associated With Suboptimal Outcomes Without Cost Savings in Inflammatory Bowel Diseases.
Giese-Kim N; Wu M; Dehghan M; Sceats LA; Park KT
Am J Gastroenterol; 2020 Oct; 115(10):1698-1706. PubMed ID: 32701731
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
